Ascendis Pharma A/S (NASDAQ:ASND) Q4 2025 Earnings Call Transcript
Operator: At this time, participants are in listen-only mode. Thank you for standing by, and welcome to the Ascendis Pharma A/S Fourth Quarter 2025 Earnings Conference Call.
Ascendis Pharma A/S (ASND)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,281,496 | $2,192,426,207 | 22.46% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 5,111,111 | $1,089,893,310 | +1% | 10.71% |
| 3. | Perceptive Advisors Joseph Edelman | 1,081,421 | $230,602,214 | -1% | 4.11% |
| 4. | Citadel Investment Group Ken Griffin | 519,516 | $110,781,591 | +1780% | 0.02% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 370,473 | $78,999,663 | -57% | 0.31% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,185,696 | $1,105,797,733 | 4.61% | |
| 2. | 4,153,311 | $885,651,945 | 0.05% | |
| 3. | 4,061,641 | $866,104,326 | 0.39% | |
| 4. | 3,225,885 | $687,887,701 | 1.03% | |
| 5. | 3,063,943 | $653,355,205 | 0.1% |
News See All
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy.
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT
In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pharma from $322 to $330, keeping an Overweight rating on the stock.
11 Best Stocks to Buy for Investment
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.
10 High Growth European Stocks To Buy
European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood...
Ascendis Pharma A/S (ASND): A Bull Case Theory
We came across a bullish thesis on Ascendis Pharma A/S on Tip Ranks’ YouTube Channel. In this article, we will summarize the bulls’ thesis on ASND.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Third Quarter 2025 Pharma Earnings Conference Call. At this time, participants are in a listen-only mode.
UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best biotech stocks to buy.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
Hedge Fund Resource Center Billionaire Hedge Funds
